JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

14.85 -1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.82

Máximo

15.13

Indicadores-chave

By Trading Economics

Rendimento

-14M

-25M

Vendas

-5.5M

66M

Margem de lucro

-38.059

Funcionários

342

EBITDA

-14M

-19M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+43% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-68M

1.7B

Abertura anterior

15.85

Fecho anterior

14.85

Sentimento de Notícias

By Acuity

34%

66%

78 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de jul. de 2025, 17:53 UTC

Grandes Movimentos do Mercado

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 de jul. de 2025, 15:58 UTC

Ganhos
Grandes Movimentos do Mercado

Aon Shares Rise After 2Q Earnings Beat

25 de jul. de 2025, 15:08 UTC

Grandes Movimentos do Mercado

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 de jul. de 2025, 21:40 UTC

Conversa de Mercado

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 de jul. de 2025, 21:23 UTC

Conversa de Mercado

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 de jul. de 2025, 20:40 UTC

Ganhos

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 de jul. de 2025, 20:10 UTC

Ganhos

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 de jul. de 2025, 19:56 UTC

Ganhos

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 de jul. de 2025, 19:14 UTC

Conversa de Mercado

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 de jul. de 2025, 19:10 UTC

Conversa de Mercado

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 de jul. de 2025, 19:01 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 de jul. de 2025, 18:45 UTC

Conversa de Mercado

Gold Ends Down Week on Lower Note -- Market Talk

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 de jul. de 2025, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 de jul. de 2025, 17:38 UTC

Grandes Movimentos do Mercado

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 de jul. de 2025, 17:26 UTC

Conversa de Mercado

U.S. Oil Rig Count Extends Decline -- Market Talk

25 de jul. de 2025, 17:13 UTC

Ganhos

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 de jul. de 2025, 16:46 UTC

Ganhos

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 de jul. de 2025, 16:45 UTC

Ganhos

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 de jul. de 2025, 16:27 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

25 de jul. de 2025, 16:02 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 de jul. de 2025, 15:34 UTC

Ganhos

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 de jul. de 2025, 15:06 UTC

Conversa de Mercado

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 de jul. de 2025, 15:05 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 de jul. de 2025, 14:45 UTC

Conversa de Mercado

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 de jul. de 2025, 14:44 UTC

Conversa de Mercado

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 de jul. de 2025, 14:36 UTC

Conversa de Mercado
Ganhos

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

43% parte superior

Previsão para 12 meses

Média 21.25 USD  43%

Máximo 29 USD

Mínimo 18 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

78 / 375 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.